$0.090000
-0.06-66.67%
At close: Jul 5, 1:38 PM EDT
$0.041000
-0.05-54.44%
After Hours: May 10, 4:02 PM EDT
15 minutes delayed
Acutus Medical
AFIBOTCPK
Acutus Medical (OTC:AFIB) Stock, Analyst Ratings, Price Targets, Forecasts
Acutus Medical Inc has a consensus price target of $1.5 based on the ratings of 10 analysis. The 3 most-recent analyst ratings were released by Goldman Sachs, BTIG, and BTIG on August 16, 2022, June 24, 2022, and April 27, 2022, respectively. With an average price target of $1.67 between Goldman Sachs, BTIG, and BTIG, there's an implied 5455.56% upside for Acutus Medical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
BTIG
Canaccord Genuity
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Acutus Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 08/16/2022 | Buy Now | 4900% | Goldman Sachs | Amit Hazan | $1 → $1.5 | Maintains | Neutral | Get Alert |
| 06/24/2022 | Buy Now | 4900% | BTIG | Marie Thibault | $2 → $1.5 | Maintains | Buy | Get Alert |
| 04/27/2022 | Buy Now | 6566.67% | BTIG | Marie Thibault | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 04/14/2022 | Buy Now | 3233.33% | Goldman Sachs | Amit Hazan | $5 → $1 | Maintains | Neutral | Get Alert |
| 01/20/2022 | Buy Now | — | BTIG | Marie Thibault | — | Downgrade | Buy → Neutral | Get Alert |
| 01/14/2022 | Buy Now | 9900% | Canaccord Genuity | William Plovanic | $10 → $3 | Downgrade | Buy → Hold | Get Alert |
| 11/12/2021 | Buy Now | — | JP Morgan | Robbie Marcus | — | Downgrade | Neutral → Underweight | Get Alert |
| 11/12/2021 | Buy Now | 33233.33% | Canaccord Genuity | William Plovanic | — | Maintains | Buy | Get Alert |
| 10/22/2021 | Buy Now | 33233.33% | Goldman Sachs | Amit Hazan | — | Initiates | → Neutral | Get Alert |
| 07/15/2021 | Buy Now | 59900% | Canaccord Genuity | William Plovanic | — | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Acutus Medical (AFIB) stock?
The latest price target for Acutus Medical (OTCPK:AFIB) was reported by Goldman Sachs on August 16, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 4900.00% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acutus Medical (AFIB)?
The latest analyst rating for Acutus Medical (OTCPK:AFIB) was provided by Goldman Sachs, and Acutus Medical maintained their neutral rating.
When was the last upgrade for Acutus Medical (AFIB)?
The last upgrade for Acutus Medical Inc happened on April 27, 2022 when BTIG raised their price target to $2. BTIG previously had a neutral for Acutus Medical Inc.
When was the last downgrade for Acutus Medical (AFIB)?
The last downgrade for Acutus Medical Inc happened on January 20, 2022 when BTIG changed their price target from N/A to N/A for Acutus Medical Inc.
When is the next analyst rating going to be posted or updated for Acutus Medical (AFIB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
Is the Analyst Rating Acutus Medical (AFIB) correct?
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $0.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.